Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Operating Leases (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Operating Leases for 3 consecutive years, with $66000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 67.33% to $66000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66000.0 through Dec 2025, down 67.33% year-over-year, with the annual reading at $66000.0 for FY2025, 67.33% down from the prior year.
  • Operating Leases hit $66000.0 in Q4 2025 for NewAmsterdam Pharma, down from $85000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $328000.0 in Q2 2024 to a low of $57133.9 in Q4 2022.
  • Historically, Operating Leases has averaged $155516.7 across 3 years, with a median of $120000.0 in 2025.
  • Biggest YoY gain for Operating Leases was 67.33% in 2025; the steepest drop was 68.6% in 2025.
  • Year by year, Operating Leases stood at $57133.9 in 2022, then surged by 253.56% to $202000.0 in 2024, then tumbled by 67.33% to $66000.0 in 2025.
  • Business Quant data shows Operating Leases for NAMS at $66000.0 in Q4 2025, $85000.0 in Q3 2025, and $103000.0 in Q2 2025.